Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Comparing outcomes of concurrent chemotherapy regimens in patients 65 years or older with locally advanced oropharyngeal carcinoma.

Amini A, Eguchi M, Jones BL, Stokes WA, Gupta A, McDermott JD, Massarelli E, Bradley CJ, Karam SD.

Cancer. 2018 Oct 6. doi: 10.1002/cncr.31740. [Epub ahead of print]

PMID:
30291789
2.

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B.

JAMA Oncol. 2018 Sep 27. doi: 10.1001/jamaoncol.2018.4051. [Epub ahead of print]

PMID:
30267032
3.

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R.

J Immunother Cancer. 2018 Jun 4;6(1):46. doi: 10.1186/s40425-018-0361-7. Review.

4.

Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients.

Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, Vora L, Maghami E, Kortylewski M.

Oncotarget. 2018 Feb 2;9(13):11279-11290. doi: 10.18632/oncotarget.24397. eCollection 2018 Feb 16.

5.

Perspectives in Head and Neck Medical Oncology.

Amanam I, Gupta R, Mita A, Scher K, Massarelli E.

Cancer Treat Res. 2018;174:163-185. doi: 10.1007/978-3-319-65421-8_10.

PMID:
29435842
6.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

7.

Checkpoint inhibitors in lung cancer: latest developments and clinical potential.

Schvartsman G, Ferrarotto R, Massarelli E.

Ther Adv Med Oncol. 2016 Nov;8(6):460-473. Epub 2016 Jul 26. Review.

8.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

9.

Immune Checkpoint Therapy in Head and Neck Cancers.

Msaouel P, Massarelli E.

Cancer J. 2016 Mar-Apr;22(2):108-16. doi: 10.1097/PPO.0000000000000180. Review.

PMID:
27111906
10.

New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic.

Massarelli E, Ferrarotto R, Glisson BS.

Clin Cancer Res. 2015 Sep 1;21(17):3821-8. doi: 10.1158/1078-0432.CCR-14-1329. Review.

11.

Human Lung Fibroblasts Inhibit Non-Small Cell Lung Cancer Metastasis in Ex Vivo 4D Model.

Mishra DK, Compean SD, Thrall MJ, Liu X, Massarelli E, Kurie JM, Kim MP.

Ann Thorac Surg. 2015 Oct;100(4):1167-74; discussion 1174. doi: 10.1016/j.athoracsur.2015.05.014. Epub 2015 Jul 30.

PMID:
26233278
12.

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29.

13.

Immunotherapy in lung cancer.

Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS.

Transl Lung Cancer Res. 2014 Feb;3(1):53-63. doi: 10.3978/j.issn.2218-6751.2014.01.01. Review.

14.

Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer.

Massarelli E, Papadimitrakopoulou V.

Clin Cancer Res. 2015 Feb 15;21(4):670-4. doi: 10.1158/1078-0432.CCR-14-1291. Epub 2015 Jan 6. Review. Erratum in: Clin Cancer Res. 2015 May 15;21(10):2412.

15.

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW.

Cancer Immunol Res. 2014 Sep;2(9):831-8. doi: 10.1158/2326-6066.CIR-14-0069. Review.

16.

Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA.

Clin Lung Cancer. 2014 Sep;15(5):379-86. doi: 10.1016/j.cllc.2014.04.002. Epub 2014 May 14.

17.

Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.

Massarelli E, Johnson FM, Erickson HS, Wistuba II, Papadimitrakopoulou V.

Lung Cancer. 2013 Jun;80(3):235-41. doi: 10.1016/j.lungcan.2013.01.018. Epub 2013 Feb 26. Review.

PMID:
23485129
18.

CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.

Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS.

Cancer Res. 2013 Jan 15;73(2):571-82. doi: 10.1158/0008-5472.CAN-12-0263. Epub 2012 Nov 30.

19.

Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer.

Massarelli E, Papadimitrakopoulou VA.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S379-82. doi: 10.1097/JTO.0b013e31826df0f0. Review. No abstract available.

20.

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.

Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS.

J Thorac Oncol. 2010 Jul;5(7):1054-9.

21.

Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.

Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V.

J Clin Oncol. 2010 Jan 1;28(1):8-14. doi: 10.1200/JCO.2009.23.0425. Epub 2009 Nov 16.

22.

Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.

Tang X, Varella-Garcia M, Xavier AC, Massarelli E, Ozburn N, Moran C, Wistuba II.

Cancer Prev Res (Phila). 2008 Aug;1(3):192-200. doi: 10.1158/1940-6207.CAPR-08-0032.

23.

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II.

Clin Cancer Res. 2007 May 15;13(10):2890-6.

24.

Use of novel second-line targeted therapies in non-small cell lung cancer.

Massarelli E, Herbst RS.

Semin Oncol. 2006 Feb;33(1 Suppl 1):S9-16. Review.

PMID:
16472704
25.

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM.

Cancer Res. 2005 Dec 15;65(24):11478-85.

26.

Akt activation correlates with adverse outcome in tongue cancer.

Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA.

Cancer. 2005 Dec 1;104(11):2430-6.

27.

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S.

Clin Cancer Res. 2005 Jul 1;11(13):4741-8.

28.

Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.

Massarelli E, Brown E, Tran NK, Liu DD, Izzo JG, Lee JJ, El-Naggar AK, Hong WK, Papadimitrakopoulou VA.

Cancer. 2005 Mar 1;103(5):952-9.

29.

Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.

Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F.

Cancer. 2004 Oct 15;101(8):1733-44. Review.

30.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS.

Lung Cancer. 2004 Apr;44(1):99-110.

PMID:
15013588
31.

Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.

Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43.

32.

New targets for the treatment of advanced non-small cell lung cancer.

Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS.

Cancer Chemother Biol Response Modif. 2002;20:717-61. Review. No abstract available.

PMID:
12703232
33.

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS.

Lung Cancer. 2003 Jan;39(1):55-61.

PMID:
12499095
34.

Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.

Carlomagno C, Lauria R, De Laurentiis M, Arpino G, Massarelli E, Ferrara C, Milano A, Vernaglia Lombardi A, Costanzo R, Catalano G, Bianco AR, De Placido S.

Oncology. 2002;63(3):219-25.

PMID:
12381900
35.

Medical hypnosis and quadruplets: a case report.

Brown DC, Massarelli E.

Am J Clin Hypn. 2002 Jul;45(1):39-46.

PMID:
12116614
36.

Comparative fine structural distribution of endopeptidase 24.15 (EC3.4.24.15) and 24.16 (EC3.4.24.16) in rat brain.

Fontenele-Neto JD, Massarelli EE, Gurgel Garrido PA, Beaudet A, Ferro ES.

J Comp Neurol. 2001 Oct 1;438(4):399-410.

PMID:
11559896
37.

Differential subcellular distribution of neurolysin (EC 3.4.24.16) and thimet oligopeptidase (EC 3.4.24.15) in the rat brain.

Massarelli EE, Casatti CA, Kato A, Camargo AC, Bauer JA, Glucksman MJ, Roberts JL, Hirose S, Ferro ES.

Brain Res. 1999 Dec 18;851(1-2):261-5.

PMID:
10642854
38.

Training Spatially Homogeneous Fully Recurrent Neural Networks in Eigenvalue Space.

Massarelli E, Perfetti R.

Neural Netw. 1997 Jan;10(1):125-137.

PMID:
12662892
39.

Adolescents with chronic disease. Are they receiving comprehensive health care?

Carroll G, Massarelli E, Opzoomer A, Pekeles G, Pedneault M, Frappier JY, Onetto N.

J Adolesc Health Care. 1983 Dec;4(4):261-5.

PMID:
6643204

Supplemental Content

Loading ...
Support Center